BeOne Medicines treatment of pancreatic cancer granted orphan status
BeOne Medicines' MTA-cooperative PRMT5 inhibitor was granted FDA orphan designation as a treatment of pancreatic cancer, according to a post to the agency's website. Reference Link
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.